109906
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
托法替尼治疗重症斑秃的病例系列及文献综述
Authors He J, Yao L, Lan N, Zhu L, Lv Y
Received 29 December 2024
Accepted for publication 7 May 2025
Published 15 November 2025 Volume 2025:18 Pages 3051—3059
DOI https://doi.org/10.2147/CCID.S512037
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Michela Starace
Jiumei He,* Longyan Yao,* Na Lan, Li Zhu, Yongmei Lv
Department of Dermatology and Venereology, The Second Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, Anhui, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yongmei Lv, Department of Dermatology and Venereology, The Second Affiliated Hospital of Anhui Medical University, No. 678 Furong Road, Hefei Economic and Technological Development Zone, Hefei, Anhui, 230601, People’s Republic of China, Email yongmei_lv830@163.com
Background: Alopecia areata (AA) is an autoimmune-mediated, non-scarring hair loss disorder. With the advancement of alopecia treatment research, the efficacy of Janus kinase (JAK) inhibitors in the clinical management of AA has been increasingly evaluated.
Objective: This study reports the efficacy and safety of tofacitinib in the treatment of severe AA and presents a literature review on tofacitinib in AA.
Methods: Collect patient information on severe AA treated at a tertiary hospital from April 2023 to May 2024, and analyze their clinical treatment outcomes.
Results: All five collected patients met the criteria for refractory alopecia areata. Three of these patients achieved favorable therapeutic outcomes with mild adverse reactions, consistent with current research findings.
Conclusion: This study supports the efficacy and safety of tofacitinib in AA treatment, providing further clinical evidence for its application.
Keywords: alopecia areata, JAK-STAT pathway, tofacitinib, JAK inhibitor
Department of Dermatology and Venereology, The Second Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, Anhui, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yongmei Lv, Department of Dermatology and Venereology, The Second Affiliated Hospital of Anhui Medical University, No. 678 Furong Road, Hefei Economic and Technological Development Zone, Hefei, Anhui, 230601, People’s Republic of China, Email yongmei_lv830@163.com
Background: Alopecia areata (AA) is an autoimmune-mediated, non-scarring hair loss disorder. With the advancement of alopecia treatment research, the efficacy of Janus kinase (JAK) inhibitors in the clinical management of AA has been increasingly evaluated.
Objective: This study reports the efficacy and safety of tofacitinib in the treatment of severe AA and presents a literature review on tofacitinib in AA.
Methods: Collect patient information on severe AA treated at a tertiary hospital from April 2023 to May 2024, and analyze their clinical treatment outcomes.
Results: All five collected patients met the criteria for refractory alopecia areata. Three of these patients achieved favorable therapeutic outcomes with mild adverse reactions, consistent with current research findings.
Conclusion: This study supports the efficacy and safety of tofacitinib in AA treatment, providing further clinical evidence for its application.
Keywords: alopecia areata, JAK-STAT pathway, tofacitinib, JAK inhibitor